Advertisement

Structure-Pharmacokinetic and Pharmacodynamic Relationships of Steroidal Neuromuscular Blocking Agents

  • Johannes H. Proost
  • J. Mark K. H. Wierda
  • Dirk K. F. Meijer

Abstract

In anesthesiology there is still a need for a short-acting non-depolarizing neuromuscular blocking agent (NMBA) for intubation, replacing the depolarizing agent suxamethonium. In order to find a rational basis for the development of new short-acting NMBA’s, it is essential to know the factors governing the time course of action of this class of drugs.

Keywords

Onset Time Plasma Protein Binding Quaternary Ammonium Compound Neuromuscular Blocking Agent Effect Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Donati F. Onset of action of relaxants. Can J Anaesth 1988;35:S52-S58.CrossRefGoogle Scholar
  2. 2.
    Wierda JMKH, Proost JH. (Pre-)clinical development of new aminosteroidal nondepolarizing neuromuscular blocking agents. In: Denissen P, ed. The development of aminosteroidal neuromuscular blocking agents. Turnhout, Belgium: Interface, 1992:43–82 (ISBN 90–800975–1–9).Google Scholar
  3. 3.
    Wierda JMKH, Proost JH, Muir AW, Marshall RJ. Design of drugs for rapid onset. Anaesth Pharmacol Rev 1993;1:57–68.Google Scholar
  4. 4.
    Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358–371.PubMedGoogle Scholar
  5. 5.
    Neef C, Meijer DKF. Structure-pharmacokinetics relationship of quaternary ammonium compounds. Correlation of physicochemical and pharmacokinetic parameters. Naunyn Schmiedebergs Arch Pharmacol 1984;328:111–118.PubMedCrossRefGoogle Scholar
  6. 6.
    Van der Sluijs P, Meijer DKF. Binding of drugs with a quaternary ammonium group to alpha-1 acid glycoprotein and asialo alpha-1 acid glycoprotein. J Pharmacol Exp Ther 1985;234:703–707.PubMedGoogle Scholar
  7. 7.
    Kleef UW, Proost JH, Roggeveld J, Wierda JMKH. Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr 1993;621:65–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Marshall RJ. Cardiovascular effects of neuromuscular blocking drugs. Curr Op Anaesthesiol 1991;4:599–602.CrossRefGoogle Scholar
  9. 9.
    Donati F, Meistelman C. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J Pharmacokinet Biopharm 1991;19:537–552.PubMedCrossRefGoogle Scholar
  10. 10.
    Epstein RH, Bartkowski RR. Prediction of vecuronium block onset and time to maximum twitch depression: modification of the Sheiner-Stanski model of the neuromuscular junction. Anesthesiology 1992;77;A443.CrossRefGoogle Scholar
  11. 11.
    Armstrong DL, Lester HA. The kinetics of tubocurarine action and restricted diffusion within the synaptic cleft. J Physiol (Lond) 1979;294:365–386.Google Scholar
  12. 12.
    Glavinovic MI, Law Min JC, Kapural L, Donati F, Bevan DR. Speed of action of various muscle relaxants at the neuromuscular junction binding vs buffering hypothesis. J Pharmacol Exp Ther 1993;265:1181–1186.PubMedGoogle Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • Johannes H. Proost
    • 1
    • 2
  • J. Mark K. H. Wierda
    • 1
    • 2
  • Dirk K. F. Meijer
    • 1
    • 2
  1. 1.Department of Pharmacology and TherapeuticsUniversity Centre for PharmacyGroningenThe Netherlands
  2. 2.Research Group for Experimental Anesthesiology and Clinical PharmacologyUniversity HospitalGroningenThe Netherlands

Personalised recommendations